NewAmsterdam Pharma Company NAMS Change in AP
Change in AP at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's change in ap.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's change in AP?
- NewAmsterdam Pharma Company (NAMS) reported change in AP of -$793K in Q1 2026.
- How has NewAmsterdam Pharma Company's change in AP changed year-over-year?
- NewAmsterdam Pharma Company's change in AP decreased by 135.2% year-over-year, from $2.25M to -$793K.
- What is the long-term trend for NewAmsterdam Pharma Company's change in AP?
- Over 3 years (2021 to 2025), NewAmsterdam Pharma Company's change in AP has grown at a -6.9% compound annual growth rate (CAGR), from $6.56M to $5.3M.
- What does change in AP mean?
- Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.